PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2021
CASE
AUTH/3474/2/21 Britannia Pharmaceuticals

AUTH/3474/2/21: Ever Pharma v Britannia β€” 0844 technical support line for APO-go (No breach)

Ever Pharma challenged Britannia’s use of an 0844 business-rate number for APO-go support. Panel found the helpline was in scope but ruled…

2021
CASE
AUTH/3488/3/21 AstraZeneca

AstraZeneca breached Code over Trixeo website mobile display and missing comparator prescribing information (AUTH/3488/3/21)

PMCPA found breaches on Trixeo HCP website: generic name too small on mobile, PI not one-click on mobile, site not certified for…

2021
CASE
AUTH/3499/4/21 Daiichi-Sankyo UK

AUTH/3499/4/21: Daiichi-Sankyo website page promoted Efient and Lixiana to the public and breached a prior undertaking

A corporate website page about Efient and Lixiana was accidentally left externally accessible via site search. PMCPA ruled promotion of POMs to…

2021
CASE
AUTH/3527/6/21 Leo Pharma ⭐ Case of the Week

LEO Pharma voluntary admission: undisclosed 2019 transfers of value to patient organisations (AUTH/3527/6/21)

LEO discovered four cross-border transfers of value involving three UK patient organisations. Three 2019 payments were disclosed late and two agreements weren’t…

2021
CASE
AUTH/3528/6/21 Novartis Pharmaceuticals UK

AUTH/3528/6/21: Anonymous doctor v Advanced Accelerator Applications (AAA) – third-party CPD alleged to promote unlicensed PSMA therapy

AAA-funded third-party CPD (with UK CPD accreditation) was found to include promotional claims for an unlicensed PSMA therapy. PMCPA ruled breaches for…

2021
CASE
AUTH/3541/7/21 Roche Products

Roche Resources website: illegible generic name and misleading Ocrevus dosing cadence (AUTH/3541/7/21)

Anonymous HCP challenged multiple Roche Resources pages. Panel upheld breaches for illegible Gazyvaro generic name and misleading Ocrevus β€œdosed every 6 months”…

2021
CASE
AUTH/3575/11/21 Biogen Idec

Biogen: internal fundraising email linked SMA charity donations to pressuring NHS/NICE on Spinraza (AUTH/3575/11/21)

A senior leader emailed staff urging donations to SMA charities, describing β€œpartnering” to β€œput pressure on the NHS” to fund Spinraza after…

2022
CASE
AUTH/3615/3/22 Daiichi-Sankyo UK

Daiichi Sankyo breached Code over uncertified mobile β€˜final form’ differences on Lixiana HCP and patient websites (AUTH/3615/3/22)

PMCPA ruled Daiichi Sankyo breached Clauses 8.1 and 8.3 after desktop and mobile versions of Lixiana HCP/patient webpages differed (colour and images)…

2022
CASE
AUTH/3602/1/22 Teva ⭐ Case of the Week

Teva: Ajovy website landing-page pop-up – no breach (AUTH/3602/1/22)

A UK health professional complained that the Ajovy website entry pop-up lacked the generic name and black triangle. The Panel ruled no…

2019
CASE
Novartis Pharmaceuticals UK

Novartis breached Clause 4.9 after Entresto sponsored BJC supplement articles omitted adverse event reporting statement

Five Novartis-funded Entresto promotional articles on the BJC website linked to prescribing info but omitted the adverse event reporting statement in the…

2022
CASE
AUTH/3663/6/22 Roche Products

Roche: Ocrevus prescribing information on multi-therapy β€œCongress & Meetings” hub page (AUTH/3663/6/22) – No breach

Complaint alleged off-label promotion and public advertising because Ocrevus PI appeared on a congress hub page mentioning oncology and COVID-19. PMCPA ruled…

2022
CASE
AUTH/3672/6/22 Pfizer

Pfizer press release: dark grey (not black) β–Ό symbol ruled a high-standards breach (AUTH/3672/6/22)

Pfizer’s UK website press release about Paxlovid used a dark grey (not black) β–Ό symbol. Panel ruled breach of Clause 5.1 (high…

2022
CASE
AUTH/3701/10/22 Janssen

AUTH/3701/10/22: Astellas v Janssen β€” Nurse support service for Erleada (apalutamide) offered as a package deal (No breach)

Astellas alleged Janssen’s Erleada nurse support service (package deal) induced prescribing. The Panel found Astellas did not evidence wrongdoing and ruled no…

2021
CASE
AstraZeneca ⭐ Case of the Week

AstraZeneca breach over Trixeo ad implying mortality benefit (Pulse magazine)

Pulse ad for Trixeo linked COPD exacerbations and death with a β€œTake action with Trixeo” call-to-action, creating an unsubstantiated and misleading implication…

2019
CASE
Pfizer

Pfizer: UK senior employee retweeted US post about unlicensed COVID-19 vaccine candidate on Twitter (ABPI Code 2019)

A senior UK Pfizer employee retweeted a US colleague’s tweet claiming 95% efficacy for a COVID-19 vaccine candidate before UK authorisation, with…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training